ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global ...
Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...
According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold 395,617 shares of CRISPR Therapeutics AG during the third quarter. Its ...
Only one in every six million people have the Rh null blood type. Now researchers are trying to grow it in the laboratory in ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...
Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...
Liver cells are indispensable for research—for drug testing, to better understand diseases such as hepatitis, fatty liver, cirrhosis, or liver cancer and for development of future cell therapies.
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol ...
The market is driven by advancements in gene therapy, stem cell-based treatments, and increasing investment in rare diseases. Despite high costs, the market for these innovative treatments is growing, ...
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback